Evaluation of Immunogenicity and Safety of Combined Immunization of COVID-19 Vaccine (Produced in Beijing) and PPV23 / IIV4

NCT04790851 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

1133

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza, Human
Pneumonia, Pneumococcal
Covid19

Interventions

BIOLOGICAL: COVAX+IIV4; COVAX+PPV23
BIOLOGICAL: COVAX only (1st and 2nd dose)
BIOLOGICAL: IIV4 for the 1st dose and PPV23 for the 2nd dose

Sponsor

China National Biotec Group Company Limited

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]